OneMedNet Corp 10-K

Item 8. Financial Statements and Supplementary Data ONEMEDNET CORPORATION INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-1 Consolidated Balance Sheets F-3 Consolidated Statements of Operations F-4 Consolidated Statements of Changes in Stockholders’ Deficit F-5 Consolidated Statements of Cash Flows F-6 Notes to the Consolidated Financial Statements F-7 39 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of OneMedNet Corporation: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of OneMedNet Corporation (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring operating losses and negative cash flows from operating activities since inception and expects to continue incurring operating losses and negative cash flows in the future. These matters raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. F- 1 Emphasis of Matter – Crypto Assets Risks Associated with Crypto Assets and Risks of Ownership As of the date of these consolidated financial statements, digital assets are loosely regulated and there is no central marketplace or currency exchange. Supply is not determined by a central bank, and prices have been extremely volatile during the periods presented in the financial statements. Transferability and ownership of digital assets is verified by a thirty-two-character cryptographic key. Digital asset exchanges in the marketplace have been closed due to fraud, failure or security breaches. Any of the Company’s digital assets that reside on an exchange that shuts down may be lost. Several factors may affect the price of digital assets, including, but not limited to, supply and demand, investors’ expectations with respect to the rate of inflation, interest rates, currency exchange rates or future regulatory measures (if any) that restrict the trading of digital assets or the use of digital assets as a form of payment. There is no assurance that digital assets will maintain their long-term value in terms of purchasing power in the future, or that acceptance of digital asset payments by mainstream retail merchants and commercial businesses will continue to grow. Risks Associated With Crypto Asset Regulation As digital assets have grown in popularity and market size, various countries and jurisdictions have begun to develop regulations governing the digital assets industry. To the extent that future regulatory actions or policies limit the ability to exchange digital assets or utilize them for payments, the demand for digital assets will be reduced. Furthermore, regulatory actions may limit the ability of end-users to convert digital assets into fiat currency (e.g., U.S. dollars) or use digital assets to pay for goods and services. Such regulatory actions or policies would result in a reduction of demand, and in turn, a decline in the underlying digital asset unit prices. The effect of any future regulatory change on the Company or digital assets in general is impossible to predict, but such change could be substantial and adverse to the Company and the value of the Company’s investments in digital assets. Risks Associated With No FDIC or SIPC Protection The Company’s crypto assets are held by a custodian that is not a banking institution or otherwise a member of the Federal Deposit Insurance Corporation (“FDIC”) or the Securities Investor Protection Corporation (“SIPC”). Accordingly, deposits or assets held by the custodian are not subject to the protections enjoyed by depositors with FDIC or SIPC member institutions. /s/ WithumSmith+Brown, PC We have served as the Company’s auditor since 2024. East Brunswick, New Jersey March 30, 2026 PCAOB ID Number 100 F- 2 ONEMEDNET CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) 2025 2024 As of December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 585 $ 172 Investment in crypto assets – Bitcoin 506 2,849 Accounts receivable, net 495 213 Prepaid expenses and other current assets 509 385 Total current assets 2,095 3,619 Property and equipment, net 56 108 Total assets $ 2,151 $ 3,727 Liabilities and stockholders’ deficit Current liabilities: Accounts payable and accrued expenses $ 3,496 $ 6,038 Deferred revenues 389 561 Loans payable 754 3,608 Loans payable – related parties - 2,319 Convertible notes at fair value - 3,452 Deferred underwriter fee payable - 3,250 SEPA put option liability 186 - Total current liabilities 4,825 19,228 Loans payable, net of current portion 220 - Warrant liabilities 71 15 SEPA put option liability, net of current portion - 434 Total liabilities 5,116 19,677 Commitments and contingencies (Note 13) - - Stockholders’ deficit: Preferred Stock, par value $ 0.0001 , 1,000,000 authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 - - Common Stock, par value $ 0.0001 , 100,000,000 shares authorized, 52,172,219 shares issued and 51,984,474 shares outstanding at December 31, 2025, and 28,175,172 shares issued and 27,987,427 shares outstanding at December 31, 2024 2 2 Additional paid-in-capital 101,932 86,146 Treasury stock, at cost, 187,745 shares at December 31, 2025 and 2024 ( 529 ) ( 529 ) Accumulated deficit ( 104,370 ) ( 101,569 ) Total stockholders’ deficit ( 2,965 ) ( 15,950 ) Total liabilities and stockholders’ deficit $ 2,151 $ 3,727 The accompanying notes are an integral part of these consolidated financial statements. F- 3 ONEMEDNET CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data) 2025 2024 Year Ended December 31, 2025 2024 Revenue Subscription revenue $ 105 $ 351 Data delivery revenue 1,254 292 Total revenue 1,359 643 Cost of revenue 1,862 924 Gross margin ( 503 ) ( 281 ) Operating expenses General and administrative 6,377 7,027 Sales and marketing 1,272 830 Research and development 1,515 1,467 Total operating expenses 9,164 9,324 Loss from operations ( 9,667 ) ( 9,605 ) Other (income) expense, net Interest expense 67 147 Change in fair value of warrants 56 ( 9 ) Change in fair value of convertible notes ( 1,285 ) 808 Change in fair value of crypto assets – Bitcoin 945 ( 798 ) Realized gain on sale of crypto assets – Bitcoin ( 922 ) ( 120 ) Change in fair value of SEPA derivative liabilities ( 216 ) 434 Gain on troubled debt restructurings ( 5,569 ) - Loss on extinguishment of debt 41 - Other expense 16 60 Total other (income) expense, net ( 6,867 ) 522 Loss before income taxes $ ( 2,800 ) $ ( 10,127 ) Income tax expense 1 2 Net loss $ ( 2,801 ) $ ( 10,129 ) Earnings per share: Basic and diluted net loss per common share outstanding $ ( 0.06 ) $ ( 0.36 ) Basic and diluted weighted average number of common shares outstanding 44,547,815 28,076,512 The accompanying notes are an integral part of these consolidated financial statements. F- 4 ONEMEDNET CORPORATION CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT (In thousands, except share data) Shares Amount Shares Amount Capital Deficit Deficit Additional Total Common Stock Treasury Stock Paid-in Accumulated Stockholders’ Shares Amount Shares Amount Capital Deficit Deficit Balances as of December 31, 2023 23,572,232 $ 2 - $ - $ 77,996 $ ( 91,440 ) $ ( 13,442 ) Issuance of common stock to settle deferred underwriter fee payable 277,778 - - - 242 - 242 Repurchase of common stock - - ( 187,745 ) ( 529 ) - - ( 529 ) Vesting of restricted stock units 200,000 - - - - - - Issuance of common stock and pre-funded warrants in connection with private placements, net of issuance costs 3,598,850 - - - 6,270 - 6,270 Issuance of common stock to settle Yorkville commitment fee 526,312 - - - 500 - 500 Issuance of warrants to terminate Helena SPA - - - - 35 - 35 Extinguishment of officer accrued salaries - - - - 132 - 132 Partial conversion of Yorkville Note - - - - 343 - 343 Stock-based compensation expense - - - - 628 - 628 Net loss - - - - - ( 10,129 ) ( 10,129 ) Balances as of December 31, 2024 28,175,172 $ 2 ( 187,745 ) $ ( 529 ) $ 86,146 $ ( 101,569 ) $ ( 15,950 ) Balances 28,175,172 $ 2 ( 187,745 ) $ ( 529 ) $ 86,146 $ ( 101,569 ) $ ( 15,950 ) Issuance of common stock in connection with private placements, net of issuance costs 4,864,619 - - - 2,497 - 2,497 Issuance of common stock upon partial conversions of Yorkville Note 1,866,562 - - - 1,392 - 1,392 Issuance of common stock in connection with settlement of vendor payable 250,000 - - - 111 - 111 Issuance of common stock upon conversions of loans with related parties 3,166,475 - - - 2,334 - 2,334 Issuance of common stock upon conversions of PIPE Notes 1,453,174 - - - 510 - 510 Issuance of common stock upon conversions of loan extensions with related parties 3,650,248 - - - 2,584 - 2,584 Issuance of common stock in connection with subscription agreements with related parties 3,438,538 - - - 1,697 - 1,697 Issuance of common stock in connection with exercises of pre-funded warrants 3,048,232 - - - - - - Issuance of common stock in connection with exercises of Helena Termination Warrants 50,000 - - - 60 - 60 Issuance of common stock in connection with Yorkville SEPA 1,020,880 - - - 2,569 - 2,569 Issuance of common stock for consulting services rendered 30,000 - - - 70 - 70 Vesting of restricted stock units 970,574 - - - - - - Stock-based compensation expense - - - - 1,962 - 1,962 Net loss - - - - - ( 2,801 ) ( 2,801 ) Balances as of December 31, 2025 51,984,474 $ 2 ( 187,745 ) $ ( 529 ) $ 101,932 $ ( 104,370 ) $ ( 2,965 ) Balances 51,984,474 $ 2 ( 187,745 ) $ ( 529 ) $ 101,932 $ ( 104,370 ) $ ( 2,965 ) The accompanying notes are an integral part of these consolidated financial statements. F- 5 ONEMEDNET CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) 2025 2024 Year Ended December 31, 2025 2024 Cash flows from operating activities: Net loss $ ( 2,801 ) $ ( 10,129 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 65 57 Stock-based compensation expense 2,032 628 Stock warrant expense - 35 Change in fair value of warrant liabilities 56 ( 9 ) Change in fair value of convertible notes ( 1,285 ) 808 Change in fair value of crypto assets – Bitcoin 945 ( 798 ) Change in fair value of SEPA derivative liabilities ( 216 ) 434 Realized gain on sale of crypto assets – Bitcoin ( 922 ) ( 120 ) Gain on troubled debt restructurings ( 5,569 ) - Loss on debt extinguishment 41 - Non-cash SEPA commitment fee - 500 Gain on forgiveness of CEBA loan - ( 15 ) Non-cash interest 45 121 Change in operating assets and liabilities: Accounts receivable ( 282 ) ( 61 ) Prepaid expenses and other current assets 194 84 Accounts payable and accrued expenses 366 1,206 Deferred revenues ( 172 ) 307 Net cash used in operating activities ( 7,503 ) ( 6,952 ) Cash flows from investing activities: Purchases of property and equipment ( 13 ) ( 51 ) Purchases of crypto assets – Bitcoin ( 2,750 ) ( 2,900 ) Proceeds from sales of crypto assets – Bitcoin 5,070 969 Net cash provided by (used in) investing activities 2,307 ( 1,982 ) Cash flows from financing activities: Proceeds from private placements, net of issuance costs 2,497 6,270 Proceeds from related party subscription agreements, net of issuance costs 1,697 - Proceeds from Yorkville SEPA 2,537 - Proceeds from exercises of Helena Termination Warrants 60 - Repayment of deferred underwriter fees ( 500 ) ( 100 ) Repayment of Yorkville Note ( 262 ) - Repayment of loans payable ( 401 ) ( 231 ) Payment of issuance costs in connection with non-cash conversions of liabilities ( 19 ) - Proceeds from issuance of shareholder loans - 2,000 Proceeds from issuance of Yorkville Note, net of issuance costs - 1,350 Proceeds from line of credit borrowings - 500 Repayment of CEBA loan - ( 30 ) Repayment of shareholder loan - ( 200 ) Repayment of line of credit borrowings - ( 500 ) Net cash provided by financing activities 5,609 9,059 Net increase in cash and cash equivalents 413 125 Cash and cash equivalents at beginning year 172 47 Cash and cash equivalents at end of year $ 585 $ 172 Supplemental disclosure of cash flow information: Cash paid for interest $ 23 $ 26 Cash paid for taxes $ 1 $ 18 Supplemental disclosures of non-cash investing and financing activities: Issuance of common stock in connection with settlement of vendor payable $ 111 $ 242 Issuance of common stock upon partial conversions of Yorkville Note $ 1,392 $ - Issuance of common stock upon conversions of loans with related parties $ 2,334 $ - Issuance of common stock upon conversion of PIPE Notes $ 510 $ - Issuance of common stock upon conversion of loan extensions with related parties $ 2,584 $ - Insurance premium settled by issuance of note payable $ 317 $ 318 Common stock repurchase consideration in loans payable $ 312 $ 329 Common shares issued to partially settle deferred underwriter fees $ - $ 242 Recognition of prepaid forward contract in exchange for partial conversion of Yorkville Note $ - $ 343 Extinguishment of officer accrued salaries reclassified to additional paid-in capital $ - $ 132 The accompanying notes are an integral part of these consolidated financial statements. F- 6 ONEMEDNET CORPORATION NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. Description of Business Organization and Description of Business OneMedNet Corporation (the “Company”) is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. The Company was founded in Delaware on November 20, 2015. The Company has been solely focused on creating solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc. (“OneMedNet Canada”), incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia. The Company’s headquarters location is Eden Prairie, Minnesota. On November 7, 2023, the Company consummated a merger (the “Merger”) following the approval at the special meeting of the shareholders of Data Knights Acquisition Corp. (“Data Knights”), a Delaware corporation, held on October 17, 2023 (the “Special Meeting”), of the agreement and plan of merger, dated as of April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Data Knights Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Data Knights, OneMedNet Solutions Corporation (formerly named OneMedNet Corporation) (“Legacy ONMD”), Data Knights, LLC, a Delaware limited liability company (“Sponsor”), and Paul Casey, in his capacity as representative of the stockholders of Legacy ONMD. Pursuant to the Merger Agreement, Merger Sub merged with and into Legacy ONMD, with Legacy ONMD surviving the Merger as a wholly-owned subsidiary of Data Knights (such transactions contemplated by the Merger Agreement, the “Business Combination”). Risks and Uncertainties The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. The Company has incurred recurring net losses since its inception, including $ 2.8 million and $ 10.1 million for the years ended December 31, 2025 and 2024, respectively. In addition, the Company had an accumulated deficit of $ 104.4 million as of December 31, 2025. The Company’s cash balance of $ 0.6 million is not adequate to fund its operations through at least twelve months from the date these consolidated financial statements were available for issuance. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. To continue in existence and expand its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt offering and ultimately attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to continue receiving working capital cash payments and generating cash flow from operations. F- 7 Investment in Crypto Assets – Bitcoin The Company has also invested in Bitcoin, which is a crypto asset. Crypto assets are loosely regulated and there is no central marketplace for currency exchange. Supply is determined by a computer code, not by a central bank, and prices have been extremely volatile. Certain crypto asset exchanges have been closed due to fraud, failure or security breaches. Any of the Company’s crypto assets that reside on an exchange that shuts down may be lost. Several factors may affect the price of crypto assets, including, but not limited to: supply and demand, investors’ expectations with respect to the rate of inflation, interest rates, currency exchange rates or future regulatory measures (if any) that restrict the trading of crypto assets, and the use of crypto assets as a form of payment. There is no assurance that crypto assets will maintain their long-term value in terms of purchasing power in the future, or that acceptance of crypto asset payments by mainstream retail merchants and commercial businesses will continue to grow. As crypto assets have grown in popularity and market size, various countries and jurisdictions have begun to develop regulations governing the crypto asset industry. To the extent future regulatory actions or policies limit the ability to exchange crypto assets or utilize them for payments, the demand for crypto assets could be reduced. Furthermore, regulatory actions may limit the ability of end-users to convert crypto assets into fiat currency (e.g., U.S. dollars) or use crypto assets to pay for goods and services. Such regulatory actions or policies could result in a reduction of demand, and in turn, a decline in the underlying crypto asset unit prices. The effect of any future regulatory change on crypto assets in general is impossible to predict, but such change could be substantial and adverse to the Company and the value of the Company’s investments in crypto assets. Crypto assets are not insured or protected under the Federal Deposit Insurance Corporation (“FDIC”) or the Securities Investor Protection Company (“SIPC”). Accordingly, with respect to its Bitcoin investment, the Company does not enjoy the protections of other assets covered by the FDIC or SIPC. 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding annual financial reporting. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The accompanying consolidated financial statements include the accounts of OneMedNet Corporation, formerly Data Knights, and its wholly-owned subsidiary, OneMedNet Technologies Canada Ltd. All intercompany transactions and balances have been eliminated in consolidation. Principles of Consolidation The consolidated financial statements include the accounts of the Company, including its subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in these notes to the consolidated financial statements. Actual results and outcomes may differ materially from management’s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, the valuation of the liability classified warrants, SEPA put option liability, convertible debt measured at fair value, revenue recognition and provision for income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. F- 8 Foreign Currency The Company’s functional currency, including that of the Company’s Canadian subsidiary, OneMedNet Canada, is the United States dollar. Foreign currency gains and losses resulting from remeasurement of assets and liabilities held in foreign currencies and transactions settled in a currency other than the functional currency are included separately as non-operating income or expense in the consolidated statements of operations as a component of other (income) expense, net. The foreign currency amounts recorded for the periods presented were insignificant. Operating Segments Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. The Company considers its chief executive officer to be the Company’s CODM. The CODM manages its operations and allocates resources based on the Company’s consolidated results and therefore operates as one segment. The Company’s operations consist of its real-world data (“RWD”) platform, which enables life sciences and healthcare customers to access curated clinical and imaging datasets, as well as its legacy data exchange (BEAM) platform that facilitates the secure exchange and aggregation of medical imaging data. The Company decommissioned its legacy BEAM platform in May 2025 as part of its strategic transition to a unified real-world data platform. Revenue associated with the BEAM platform was generated through the date of decommissioning and will not continue in future periods. The Company’s method for measuring segment profitability is operating loss, which the CODM uses to assess performance and make decisions for resource allocation, consistent with the measurement principles for operating loss as reported on the Company’s consolidated statements of operations. The CODM uses consolidated operating loss to set budgets, evaluate margins, review actual results, and to make decisions whether to engage in capital management transactions. The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company’s consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources. The Company’s disaggregation of revenue by major product offering is consistent with its presentation on the Company’s consolidated statements of operations. The table below provides the Company’s total revenue by geographic region based on the location of the customer (in thousands): Schedule of Revenue by Geographic Region 2025 2024 Year Ended December 31, 2025 2024 Americas $ 608 $ 401 Europe and Middle East 695 242 Asia Pacific 56 - Total $ 1,359 $ 643 See Accounts Receivable and Allowance for Credit Losses section below for details on customers that accounted for more than 10 % of total accounts receivable and total revenue as of and for the years ended December 31, 2025 and 2024, respectively. Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid, short-term investments with a maturity of three months or less when purchased. Cash equivalents consist of money market funds and are carried at cost, which approximates fair value. The balances, at times, may exceed FDIC insured limits. The Company believes that, as of December 31, 2025 and 2024, its risk relating to deposits exceeding federally insured limits was not significant. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. As of December 31, 2025, the Company’s cash equivalents consisted of $ 0.03 million in money market funds. The Company had no cash equivalents as of December 31, 2024. F- 9 Investment in Crypto Assets The Company reflects crypto assets held at fair value on the consolidated balance sheets and consolidated statements of cash flows, the activity from remeasurement of crypto assets at fair value on the consolidated statements of operations, and the required disclosures in Note 3, Investment in Crypto Assets – Bitcoin . Crypto assets are generally valued using prices as reported on reputable and liquid exchanges based on the quoted end-of-day price provided by such exchanges as of the date and time of determination. The time used is 23:59 UTC. Accounts Receivable and Allowance for Credit Losses Accounts receivable are unsecured, recorded at net realizable value, and do not bear interest. Unbilled receivables arise when data delivery revenue is recognized and the Company has an unconditional right to consideration and only the passage of time is required to receive the consideration. Accounts receivable are considered past due if not paid within the terms established between the Company and the customer. Amounts are only written off after all attempts at collections have been exhausted. The Company determines the need for an allowance for credit losses based upon factors surrounding the credit risk of specific customers, historical trends and other information. Accounts receivable, net includes unbilled receivables of $ 0.5 million and $ 0.2 as of December 31, 2025 and 2024, respectively. As of December 31, 2025 and 2024, the Company established allowances for credit losses of $ 0 . The Company believes its credit policies are prudent and reflect normal industry terms and business risk. The Company generally does not require collateral from its customers and generally requires payment from 0 to 90 days from the invoice date. For the year ended December 31, 2025, there were three customers that accounted for 10 % or more of total revenue. For the year ended December 31, 2024, there were two customers that accounted for 10 % or more of total revenue. The following table represents these customers’ aggregate percentage of total revenue: Schedule of Aggregate Percentage Revenue and Accounts Receivable 2025 2024 Year Ended December 31, 2025 2024 Customer 1 21 % - ● % Customer 2 15 % - ● % Customer 3 12 % - ● % Customer 4 - ● % 35 % Customer 5 - ● % 17 % Aggregate percent of revenue 48 % 52 % As of December 31, 2025, there were three customers that accounted for more than 10 % of the Company’s accounts receivable balance. As of December 31, 2024, there were two customers that accounted for more than 10 % of the Company’s accounts receivable balance. The following table represents these customers’ aggregate percentage of total accounts receivable: 2025 2024 As of December 31, 2025 2024 Customer 1 18 % ● % Customer 2 17 % - 37 % Customer 3 16 % - ● % Customer 4 - ● % 17 % Aggregate percent of accounts receivable 51 % 54 % ● Revenue and/or accounts receivable was less than 10 % of revenue and/or accounts receivable. F- 10 Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation and amortization. The straight-line method is used for computing depreciation and amortization. Assets are depreciated and amortized over their estimated useful lives ranging from three to five years. Cost of maintenance and repairs are charged to expense when incurred. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. An impairment loss would be recognized when the estimated future undiscounted net cash flows from the use of the asset are less than the carrying amount of that asset. There were no such losses during the years ended December 31, 2025 or December 31, 2024. Fair Value Option of Accounting When financial instruments contain various embedded derivatives which may require bifurcation and separate accounting of those derivatives apart from the entire host instrument, if eligible, Accounting Standards Codification (“ASC”) 825, Financial Instruments , allows issuers to elect the fair value option (“FVO”) of accounting for those instruments. The FVO may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. The FVO allows the issuer to account for the entire financial instrument at fair value with subsequent remeasurements of that fair value recorded through the statements of operations at each reporting date. A financial instrument is generally eligible for the FVO if, amongst other factors, no part of the convertible, or contingently convertible, instrument is classified in stockholders’ equity and the instrument does not contain a beneficial conversion feature at issuance. In addition, because a contingent beneficial conversion feature, if any, is not separately recognized within stockholders’ equity at the issuance date, a convertible debt instrument with a contingent beneficial conversion feature is therefore eligible for the FVO if all other criteria are met. Based on the eligibility assessment discussed above, the Company concluded that its convertible notes payable is eligible for the FVO and accordingly elected the FVO for those debt instruments. This election was made because of operational efficiencies in valuing and reporting for these debt instruments in their entirety at each reporting date. The PIPE Notes and Yorkville Note contained embedded derivatives, which required bifurcation and separate accounting under GAAP, for which the Company elected the FVO. In addition, certain term PIPE Notes were issued with separately exercisable and freestanding warrants to purchase common stock, were issued with substantial discounts at issuance and contained certain embedded derivatives to be bifurcated and accounted for separately for those term notes, unless the FVO is eligible and elected. Accordingly, the Company qualified for and elected the FVO for the entire PIPE Notes instruments. The convertible debt and accrued interest at their stated interest rates were initially recorded at fair value as liabilities on the consolidated balance sheets and were subsequently re-measured at fair value at the end of each reporting period presented within the consolidated financial statements. The changes in the fair value of the convertible promissory notes, PIPE Notes and Yorkville Note are recorded in changes in fair value of convertible notes, included as a component of other (income) expenses, net, in the consolidated statements of operations. The change in fair value related to the accrued interest components is also included within the respective single line of change in fair value of convertible notes on the consolidated statements of operations. See additional information on valuation methodologies and significant assumptions used in Note 7 and Note 11. F- 11 Derivative Financial Instruments The Company evaluates its convertible debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging . Instruments that meet the definition of a derivative financial instrument and the equity scope exception in ASC 815-10-15-74(a) are classified as equity and are not subject to remeasurement provided that the Company continues to meet the criteria for equity classification. Instruments that are classified as liabilities are accounted for at fair value and remeasured at each reporting date until exercise, expiration, or modification that results in equity classification. Any change in the fair value of the warrants is recognized as change in fair value of warrant liabilities included as a component of other (income) expenses, net in the consolidated statements of operations. The classification of warrants, including whether warrants should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The fair value of liability-classified warrants is determined using the Black-Scholes options pricing model (“Black-Scholes model”) which includes Level 3 inputs, as shown in Note 11 to the consolidated financial statements. Modification of Equity Classified Warrants A change in the terms or conditions of a warrant is accounted for as a modification. For a warrant modification accounted for under ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over and the fair value of the original warrant immediately before its terms are modified, with each measured on the modification date. The accounting for any incremental fair value of the modified warrants over the original warrants is based on the specific facts and circumstances related to the modification. When a modification is directly attributable to an equity offering, the incremental change in fair value of the warrants is accounted for as an equity issuance cost. When a modification is directly attributable to a debt financing, the incremental change in fair value of the warrants is accounted for as a debt discount or debt issuance cost. For all other modifications, the incremental change in fair value is recognized as a deemed dividend. Debt Modifications and Extinguishments The Company evaluates all modifications to its debt obligations in accordance with ASC 470-60, Debt-Troubled Debt Restructurings by Debtors (“ASC 470-60”). A modification is a troubled debt restructuring (“TDR”) if both (1) the borrower is experiencing financial difficulty, and (2) the lender grants the borrower a concession. In determining if a company is experiencing financial difficulties for a TDR, as contemplated by the applicable standard, several factors are considered including whether the Company is currently in payment default on any debt, if there is a high probability of future default without modification, bankruptcy considerations, or if there is substantial doubt about the Company’s ability to continue as a going concern. A lender is granting a concession when the effective borrowing rate on the restructured debt is less than the effective borrowing rate on the original debt. If a debt restructuring involves a transfer of assets or the issuance of an equity interest in full satisfaction of a debt obligation, a concession is granted if the debt’s carrying amount exceeds the fair value of such assets or equity interests. The recognition and measurement of the impact of a TDR on the condensed consolidated financial statements depends on whether the fair value of consideration transferred or future undiscounted cash flows specified by the new terms are greater (gain is recorded in the condensed consolidated statements of operations for the difference) or less (no gain is recorded in the condensed consolidated statements of operations for the difference) than the carrying value of the debt. If a TDR is determined not to have occurred, the Company evaluates the modification in accordance with ASC Topic 470-50-40 (“ASC 470-50”), which requires modification to debt instruments to be evaluated to assess whether debt modification or debt extinguishment accounting is applicable. This evaluation includes analyzing whether there are significant and consequential changes to the economic substance of the debt. If the change is deemed insignificant then the change is considered a debt modification, whereas if the change is substantial the change is reflected as a debt extinguishment. If debt extinguishment guidance applies, the Company accounts for the income or loss from extinguishment of debt by comparing the difference between the reacquisition price and the net carrying amount of the debt being extinguished and recognizes this as gain or loss when the debt is extinguished. If debt modification guidance applies, no gain or loss is recorded and the effective interest rate of the debt is updated based on the carrying value of the debt and the revised future cash flows. Any previously capitalized debt issuance costs in a debt modification are amortized as interest expense over the term of the new debt instrument. F- 12 Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets. Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. When quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation hierarchy. If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2 inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. The Company has determined the estimated fair value of its financial instruments based on appropriate valuation methodologies; however, considerable judgment is required to develop these estimates. Accordingly, these estimated fair values are not necessarily indicative of the amounts the Company could realize in a current market exchange. The estimated fair values can be materially affected by using different assumptions or methodologies. The methods and assumptions used in estimating the fair values of financial instruments are based on carrying values and future cash flows. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, convertible notes payable, liability classified financial instruments and certain privately issued warrants. The carrying amounts of cash and cash equivalents and accounts payable financial instruments approximate their fair value due to their short-term nature. The carrying amount of accounts receivable is net of an allowance that reflects management’s best estimate of expected credit losses. See Note 11 for fair value measurements. Treasury Stock The Company records the repurchase of its common stock, par value $ 0.0001 per share at cost on the trade date of the transaction. These shares are considered treasury stock, which is a reduction to stockholders’ equity (deficit). Treasury stock is included in authorized and issued shares but excluded from outstanding shares. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers , which aligns revenue recognition with the transference of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. This core principle is achieved to the application of a five-step model: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue as performance obligations are satisfied. Payment terms between customers related to product and services sales vary by the type of customer, country of sale, and the products or services offered and could result in an unbilled receivable or deferred revenue balance depending on whether the performance obligation has been satisfied (or partially satisfied). F- 13 Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under Topic 606. A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied. Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the good or service is distinct. A good or service is considered distinct if the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement. The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Revenue is recognized only to the extent that it is probable that a significant reversal of revenue will not occur and when collection is considered probable. The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days. Subscription Revenue Subscription revenues are generated from the Company’s data exchange (BEAM) product, which is a medical imaging exchange platform between hospital/healthcare systems, imaging centers, physicians and patients. Subscription revenue is recognized over time as the customer consumes the benefits of the services as the Company stands ready to provide access to the programs throughout the subscription period. Subscription customers are invoiced either quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice. Data Delivery Revenue Data delivery revenues are generated from the Company’s proprietary iRWD™ (Imaging Real-World Data) platform, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, clinical research organizations, and artificial intelligence markets. Data delivery customers are invoiced in installments as the related data is delivered. Revenue from the sale of data delivery products is recognized at a point in time using an output measure of progress, which is based on the number of data units delivered relative to the total data units committed by the customer. Income Taxes The Company recognizes income taxes under the asset and liability method. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities, at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. The Company establishes a valuation allowance if it believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of all available evidence. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. F- 14 Patents and Trademarks Costs associated with the submission of a patent application are expensed as incurred given the uncertainty of the patents resulting in probable future economic benefits to the Company and are included in research and development expenses on the consolidated statements of operations. Research and Development The Company accounts for its research and development (“R&D”) costs in accordance with ASC 730, Research and Development (“ASC 730”). ASC 730 requires that R&D costs are generally recognized as an expense as incurred. However, some costs associated with R&D activities that have an alternative future use (e.g., materials, equipment, facilities) may be capitalizable. For the years ended December 31, 2025 and December 31, 2024, research and development expenditures were charged to operating expense as incurred. Stock-based Compensation The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation – Stock Compensation (“ASC 718”). The Company has issued stock options and restricted stock units (“RSUs”). In accordance with ASC 718, the Company recognizes compensation expense for all stock-based awards based on the estimated grant-date fair value. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The determination of fair value for stock options on the date of grant using an option-pricing model requires management to make certain assumptions including expected volatility, expected term, risk-free interest rate and expected dividends in addition to the Company’s common stock valuation. For RSUs, the fair value of an RSU is equal to the market price of the Company’s common stock (“Common Stock”) on the grant date. The Company recognizes forfeitures as they occur. Stock-based compensation expense for stock-based awards is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting period. Stock-based awards generally vest over three-year service periods and stock options expire after ten years. The Company records stock-based compensation expense to cost of revenue, general and administrative expense, sales and marketing expense or research and development expense based on the underlying function of the individual that was granted the stock-based compensation award. Shares issued upon stock option exercise and RSU vesting are newly issued shares. Net Loss per Share The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities. Certain warrants participate in distributions of the Company. The pre-funded warrants associated with the July 2024, September 2024 and June 2025 private placements (see Note 8) are considered outstanding shares in the basic earnings per share calculation given their nominal exercise price. In addition, the shares issuable pursuant to the forward contracts are considered outstanding shares in the basic earnings per share calculation because there is no consideration (see Note 8 and Note 10). The net loss attributable to common stockholders is not allocated to the warrant holders as the warrant holders do not have a contractual obligation to share in losses. Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of Common Stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities, including outstanding RSUs under the Company’s equity incentive plan, warrants to purchase Common Stock, convertible debt, deferred underwriter fees and loan extensions have been excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding to the Company’s net loss position. F- 15 As a result of the Company reporting net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents were excluded from the computation of diluted net loss per common share for the years ended December 31, 2025 and 2024 because including them would have been antidilutive (in thousands): Schedule of Antidilutive Earnings Per Share 2025 2024 Year Ended December 31, 2025 2024 Restricted stock units 3,211,252 1,625,404 Convertible debt - 8,549,417 Warrants for common stock 12,314,114 12,364,114 Deferred underwriter fees - 3,174,999 Loan extensions 330,000 3,274,182 Total common stock equivalents 15,855,366 28,988,116 General and Administrative General and administrative expenses include all costs that are not directly related to satisfaction of customer contracts. General and administrative expenses include items for the Company’s selling and administrative functions, such as sales, finance, legal, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense. Emerging Growth Company The Company is an emerging growth company, as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has not elected to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. Reclassification Certain prior period amounts have been reclassified to conform to the current year presentation. These reclassifications had no impact on the Company’s net loss, net cash flows, or stockholders’ deficit. Recently Adopted Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in their tax rate reconciliations, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and may be applied prospectively or retrospectively. The Company adopted ASU 2023-09 on a prospective basis during the year ended December 31, 2025, and included the required disclosures in Note 6, Income Taxes . The impact of the adoption of this standard was not material to the Company’s financial statements or disclosures. F- 16 Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company does not expect the impact of the adoption of this standard to be material to its financial statements or disclosures. In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”), which allows entities to use a simplified approach when estimating credit losses for current accounts receivable and contract assets arising from revenue transactions. The standard update permits consideration of collections after the balance sheet date when estimating expected credit losses, and allows consideration of subsequent collections when estimating credit losses, reducing documentation burden. The adoption of ASU 2025-05 is effective for annual and interim periods within annual reporting periods beginning after December 15, 2025. The Company is currently evaluating the potential effect of this accounting standard update on its financial statements and related disclosures. 3. Investment in Crypto Assets – Bitcoin The Company’s crypto assets are comprised solely of Bitcoin. In accordance with ASC Topic 820, Fair Value Measurement , the Company measures the fair value of its Bitcoin based on the quoted end-of-day price on the measurement date for a single Bitcoin on an active trading platform, River.com. Management has determined that River.com, an active exchange market, represents a principal market for Bitcoin and the end-of-day quoted price is both readily available and representative of fair value (Level 1 inputs). The following table sets forth the units held, cost basis, and fair value of its investments in crypto assets, as shown on the consolidated balance sheets as of December 31, 2025 (in thousands): Schedule of Crypto Assets Held Units Cost Basis Fair Value Investments in crypto assets: Bitcoin 6 $ 653 $ 506 Total 6 $ 653 $ 506 The following table sets forth the units held, cost basis, and fair value of its investments in crypto assets, as shown on the consolidated balance sheets as of December 31, 2024 (in thousands): Units Cost Basis Fair Value Investments in crypto assets: Bitcoin 31 $ 2,051 $ 2,849 Total 31 $ 2,051 $ 2,849 The following table presents a reconciliation of the fair values of the Company’s investments in crypto assets for the year ended December 31, 2025 (in thousands): Schedule of Crypto Assets Reconciliation of Fair Values Bitcoin Balance, December 31, 2024 $ 2,849 Additions 2,750 Dispositions ( 4,148 ) Unrealized loss, net ( 945 ) Balance, December 31, 2025 $ 506 F- 17 Additions are the result of the Company acquiring Bitcoin with liquid assets from equity financings, while dispositions are the result of sales of Bitcoin. During the year ended December 31, 2025, the Company had Bitcoin dispositions of $ 4.1 million, inclusive of realized gains of $ 0.9 million. The Company uses a first-in, first-out methodology to assign costs to Bitcoin for purposes of the Bitcoin held and realized gains and losses disclosure above. Bitcoin is included in current assets in the consolidated balance sheets due to the Company’s ability to sell them in a highly liquid marketplace and its intent to liquidate its Bitcoin to support operations when needed. 4. Property and Equipment Property and equipment are summarized as of December 31 (in thousands): Schedule of Property and Equipment 2025 2024 As of December 31, 2025 2024 Computers $ 311 $ 297 Furniture and equipment 27 27 Total property and equipment 338 324 Less: accumulated depreciation ( 282 ) ( 216 ) Property and equipment, net $ 56 $ 108 Depreciation expense was $ 0.07 million and $ 0.04 million for the years ended December 31, 2025 and 2024, respectively, which is recorded within general and administrative expenses in the consolidated statements of operations. 5. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following (in thousands): Schedule of Accounts Payable and Accrued Expenses 2025 2024 As of December 31, 2025 2024 Professional fees $ 1,972 $ 4,702 Payroll liabilities 728 621 Data provider costs 505 380 Other 291 335 Total $ 3,496 $ 6,038 During the year ended December 31, 2025, the Company negotiated and settled certain trade payables owed by the Company with an aggregate carrying value of $ 3.2 million. At the time of these settlements, (1) the Company had negative cash flow from operations, historical losses, and a significant accumulated deficit that raised substantial doubt about the Company’s ability to continue as a going concern, and (2) a concession was granted to the Company, as the fair value of the consideration received by the vendors was less than the net carrying value of the payables. As a result, the Company accounted for these transactions as troubled debt restructurings in accordance with ASC 470-60. In accordance with the accounting for troubled debt restructurings, the Company derecognized the outstanding payables and recognized the consideration transferred to the vendors at fair value. The fair value of consideration transferred included $ 0.3 million in cash payments made by the Company and equity interests comprised of 250,000 shares of the Company’s Common Stock valued at $ 0.1 million. The fair value of the equity interests was determined using the closing price of the Company’s Common Stock of $ 0.45 on the agreement effective date. The difference in value between the carrying value of the payables and the fair value of consideration transferred resulted in a gain on troubled debt restructuring of $ 2.8 million for the year ended December 31, 2025 in the Company’s consolidated statements of operations. 6. Income Taxes The Company has operations in the United States and Canada. The components of income (loss) before the provision for income taxes are as follows (in thousands): Schedule of Income by Geographical Location 2025 2024 Year Ended December 31, 2025 2024 United States $ ( 2,835 ) $ ( 10,046 ) Foreign 35 ( 81 ) Total loss before income taxes $ ( 2,800 ) $ ( 10,127 ) F- 18 The components of the income tax provision for the years ended December 31, 2025 and 2024 were as follows (in thousands): Schedule of Components of Income Tax 2025 2024 As of December 31, 2025 2024 Current federal $ - $ - Current state 1 2 Current foreign - - Total current tax provision (benefit) $ 1 $ 2 Deferred federal - - Deferred state - - Deferred foreign - - Total deferred tax provision (benefit) $ - $ - Total income tax provision $ 1 $ 2 For the year ended December 31, 2025, the Company adopted ASU 2023-09 on a prospective basis. The following table is a reconciliation of the U.S. federal statutory rate of 21.0% to the effective tax rate for the year ended December 31, 2025, in accordance with ASU 2023-09: Schedule of Reconciliation Income Tax Expense December 31, 2025 Amount (in thousands) Percent Tax provision at statutory rate $ ( 588 ) 21.0 % State income taxes, net of federal benefit (1) 1 0.0 % Foreign tax effects ( 7 ) 0.3 % Effects of cross-border transactions ( 12 ) 0.4 % Nontaxable or nondeductible items ( 275 ) 9.8 % Stock-based compensation expense 85 ( 3.0 )% Change in valuation allowance 731 ( 26.1 )% Other, net 66 ( 2.4 )% ( 1.2 )% ( 1.5 )% ( 1.0 )% Effective income tax rate $ 1 0.0 % (1) During the year ended December 31, 2025, state minimum taxes in California and Massachusetts comprised greater than 50% of the tax effect in this category. The following table is a reconciliation of the U.S. federal statutory tax rate of 21.0% to the effective tax rate for the years ended December 31, 2024, prior to the adoption of ASU 2023-09: December 31, 2024 Tax provision at statutory rate 21.0 % State income taxes, net of federal benefit 1.2 % Stock-based compensation expense ( 1.0 )% Permanent differences - other ( 1.2 )% Change in fair value of convertible notes ( 1.5 )% SEPA commitment fee ( 1.0 )% Change in valuation allowance ( 17.9 )% Other, net 0.4 % Effective income tax rate 0.0 % The tax effects of temporary differences that give rise to significant components of the deferred tax assets and liabilities are as follows (in thousands): Schedule of Deferred Income Taxes 2025 2024 As of December 31, 2025 2024 Deferred tax assets Net operating loss carryforwards $ 9,198 $ 9,092 Capitalized research costs 582 584 Stock-based compensation expense 290 33 Reserves 170 - Accrued expenses 34 - Fixed assets 19 21 Other 49 4 Total gross deferred tax assets 10,342 9,734 Less: valuation allowance ( 10,342 ) ( 9,551 ) Net deferred tax assets $ - $ 183 Deferred tax liabilities Other $ - $ ( 183 ) Total deferred tax liabilities $ - $ ( 183 ) Net deferred taxes $ - $ - The Company has generated both federal and state net operating losses (NOL) of approximately $ 39.5 million and $ 16.7 million, respectively. The federal NOLs include $ 12.2 million which expire at various dates beginning in 2030 and $ 27.3 million which carry forward indefinitely. The state NOLs expire at various dates beginning in 2030. Ownership changes, as defined in the Internal Revenue Code Section 382, could limit the amount of NOLs that can be utilized annually to offset future taxable income. Generally, an ownership change occurs when the ownership percentage of 5% or greater stockholders increases by more than 50% over a three-year period. The Company’s ability to utilize its federal and state tax attributes may be limited by ownership changes that have occurred in the past or may occur in the future. The Company has not yet conducted a formal study of whether, or to what extent, past changes in control of the Company impacts its ability to utilize NOL carryforwards because such NOL carryforwards cannot be utilized until the Company achieves profitability. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company’s net deferred tax assets, which are comprised primarily of net operating loss carryforwards and research costs capitalized for tax purposes. Management has considered the Company’s history of cumulative operating losses and estimated future tax losses and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2025 and 2024. The valuation allowance increased by $ 0.8 million in 2025 primarily due to the current year net operating loss and capitalized research costs. As of December 31, 2025 and 2024, the Company had no uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has not recorded any interest or penalties for unrecognized tax benefits since its inception. The Company files federal, various state, and Canada tax returns. In the U.S., all tax years since inception remain open to examination by major tax jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the respective tax authorities if they have or will be used in a future period. In Canada, the Company is generally no longer subject to income tax examinations for the years before 2022. The Company is currently not under examination by any tax authority. On July 4, 2025, the One Big Beautiful Bill Act (“OBBB”) was enacted in the U.S. The OBBB includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act (“TCJA”) and restoration of favorable tax treatment for certain business provisions including the expensing of domestic research and development expenditures. The OBBB did not have a material impact on the Company’s consolidated financial statements or footnotes. The Company did not make any income tax payments (net of refunds received) that are required to be disclosed under ASU 2023-09. F- 19 7. Debt The following table summarizes outstanding debt for the periods indicated (in thousands): Schedule of Outstanding Debt As of December 31, 2025 2024 Convertible notes at fair value PIPE Notes $ - $ 1,734 Yorkville Note - 1,718 Convertible notes at fair value - 3,452 Related party loans Convertible - 1,600 Non-convertible - 719 Related party loans - 2,319 Loans payable Stock repurchase loan 118 329 Insurance premium loan 286 287 Extension loans 350 2,992 Loans payable 754 3,608 Long-term loans payable Extension loans 26 - Stock repurchase loan 194 - Long- term loans payable 220 - Total $ 974 $ 9,379 Convertible Notes at Fair Value PIPE Notes In June 2023, the Company entered into the PIPE SPA in which the Company was required to sell senior secured convertible notes and warrants to directors of the Company. The PIPE SPA stipulates a collateral security agreement between the Company and the directors for punctual payment and performance by the Company on its obligations to the Directors. The intellectual property of the Company serves as the collateral for the PIPE Notes. The PIPE Notes and related warrants were issued through a PIPE financing transaction, which is a form of debt and equity offering under an exemption in the securities laws for qualifying private placements by issuers of publicly traded securities. On November 7, 2023, the Company received a total of $ 1.5 million from the directors in exchange for PIPE Notes in the aggregate principal amount of $ 1.6 million (plus accrued interest of $ 0.1 million) and 95,745 warrants to acquire Common Stock. The PIPE Notes are convertible into shares of Common Stock at the PIPE Investor’s election at a conversion price equal to the lower of (i) $10.00 per share, and (ii) 92.5% of the lowest VWAP for the ten (10) trading days immediately preceding the conversion date, subject to the floor price of $1.14 (representing 20% of the closing price of the Common Stock on the last trading day before the closing of the Business Combination), or the alternative conversion ratio of the greater of the floor price and the lesser of 80% of the VWAP of the common stock as of the trading day and 80% of the price computed as the quotient of the sum of the VWAP of the Common Stock for each of the three trading days with the lowest VWAP of the Common Stock during the fifteen consecutive trading day period ending and including the trading day immediately preceding the delivery or deemed delivery of the applicable conversion notice, divided by three. All such determinations are to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock. The PIPE Notes mature on the first anniversary of the issuance date, or November 7, 2024. As of December 31, 2024, the PIPE Notes had not been repaid or converted and remained outstanding. F- 20 The Company elected the FVO of accounting for its PIPE Notes. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value adjustment is presented within other (income) expenses, net in the accompanying consolidated statements of operations under the caption change in fair value of convertible notes. The fair value adjustment during the years ended December 31, 2025 and 2024 was $( 1.2 ) million and $ 0.1 million, respectively. On June 17, 2025 and June 18, 2025, the Purchasers agreed to convert $ 1.7 million of outstanding principal and accrued interest into an aggregate of 1,453,174 shares of Common Stock, which was based on the floor price of $ 1.14 per share. As such, the net carrying amount of the PIPE Notes was adjusted to its fair value of $ 0.5 million on the conversion date and reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversions took place in June 2025. As such, there was no balance outstanding as of December 31, 2025. Yorkville Note On June 17, 2024, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP (“Yorkville”) (see Note 8). Upon entry into the SEPA, the Company issued Yorkville a $ 1.5 million convertible promissory note for $ 1.35 million in cash (after a 10 % original issue discount) (the “Yorkville Note”). The Yorkville Note does not bear interest and matures on June 17, 2025 . The Yorkville Note is convertible by Yorkville into shares of Common Stock at an aggregate purchase price based on a price per share equal to the lower of (a) $1.3408 per share (subject to downward reset upon the filing of the resale registration statement described below) or (b) 90% of the lowest daily volume-weighted average price (“VWAP”) of the Common Stock on Nasdaq during the seven trading days immediately prior to each conversion (the “Variable Price”), but which Variable Price may not be lower than the Floor Price then in effect. The “Floor Price” is $ 0.28 per share, subject to the Company’s option to reduce the Floor Price to any amounts set forth in a written notice to Yorkville. Upon the occurrence and during the continuation of an event of default (as defined in the Yorkville Note), the Yorkville Note will become immediately due and payable. The issuance of the Common Stock upon conversion of the note and otherwise under the SEPA is capped at 19.9 % of the outstanding Common Stock as of June 18, 2024. Further, the note and SEPA include a beneficial ownership blocker for Yorkville such that Yorkville may not be deemed the beneficial owner of more than 4.99 % of the Company’s Common Stock. Upon any event of default, the interest rate increases to 18 % and the full unpaid principal amount may become immediately due and payable at Yorkville’s election. The Company elected the FVO of accounting for the Yorkville Note. The estimated fair value adjustment is presented within other expense (income), net in the accompanying consolidated statements of operations under the caption change in fair value of convertible notes. The fair value adjustment during the years ended December 31, 2025 and 2024 was $( 0.1 ) million and $ 0.7 million, respectively. On December 20, 2024, Yorkville provided the Company with a form of conversion notice specifying their request to convert $ 0.2 million of outstanding principal into 245,007 shares of the Company’s Common Stock, which was based on the Variable Price of $ 0.8163 . As of December 31, 2024, the Company had not yet issued the 245,007 shares of Common Stock. The fair value of $ 0.3 million was recorded as an equity forward sale contract and was included in additional paid-in-capital in stockholders’ deficit in the consolidated balance sheets as it met the criteria for equity accounting under ASC 815. The shares were issued to Yorkville on January 22, 2025. On January 23, 2025, Yorkville provided notice specifying their request to convert $ 0.6 million of outstanding principal into 650,026 shares of Common Stock, which was based on the Variable Price of $ 0.9230 . As such, the net carrying amount was adjusted to its fair value of $ 0.9 million on the conversion date and reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversion took place in January 2025. On January 27, 2025, Yorkville provided notice specifying their request to convert $ 0.2 million of outstanding principal into 216,675 shares of Common Stock, which was based on the Variable Price of $ 0.9230 . As such, the net carrying amount was adjusted to its fair value of $ 0.2 million on the conversion date and reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversion took place in January 2025. F- 21 On May 27, 2025, Yorkville provided notice specifying their request to convert $ 0.1 million of outstanding principal into 288,001 shares of Common Stock, which was based on the Variable Price of $ 0.3472 . As such, the net carrying amount was adjusted to its fair value of $ 0.1 million on the conversion date and reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversion took place in May 2025. On June 11, 2025, Yorkville provided notice specifying their request to convert $ 0.2 million of outstanding principal into 466,853 shares of Common Stock, which was based on the Variable Price of $ 0.3213 . As such, the net carrying amount was adjusted to its fair value of $ 0.2 million on the conversion date and reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversion took place in June 2025. The following table sets forth all conversions that have taken place with Yorkville as of December 31, 2025 (in thousands, except share amounts): Schedule of Forth all Conversions that have taken Place with Yorkville Principal Converted Shares of Common Stock Issued December 20, 2024 $ 200 245,007 January 23, 2025 600 650,026 January 27, 2025 200 216,675 May 27, 2025 100 288,001 June 11, 2025 150 466,853 Total 1,250 1,866,562 On June 18, 2025, the Company repaid the remaining balance outstanding under the Yorkville Note for a total of $ 0.3 million, which consisted of the outstanding principal balance and payment premium. As such, no balance remains outstanding under the Yorkville Note as of December 31, 2025. Loans with Related Parties Convertible From January 2024 to June 2024, the Company received gross proceeds of $ 1.6 million in connection with shareholder loans with a related party investor which are convertible into 2,123,424 shares of Common Stock at a conversion price of $ 0.7535 per share. These loans did not bear interest and matured one year from issuance. On June 17, 2025, the investor provided notice to convert all $ 1.6 million of outstanding principal into 2,123,424 shares of Common Stock, which was based on the stated conversion price of $ 0.7535 per share. The conversion occurred in accordance with the conversion privileges provided in the terms of the loans and the net carrying value was reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversion took place in June 2025. Non-Convertible From April 2023 to February 2024, the Company also issued $ 0.7 million in non-convertible shareholder loans with two related party investors. These loans bore an interest rate of 8.0 % with a maturity date one year from issuance. On June 19, 2025, these investors agreed to convert $ 0.7 million of non-convertible shareholder loans outstanding into 1,043,051 shares of Common Stock at an agreed-upon conversion price of $ 0.71 per share. At the time of the conversion notices, the Company was experiencing financial difficulties (see Note 5), and a concession was granted to the Company because these loans were not convertible pursuant to their original terms and the fair value of equity interests received by the shareholders was less than the carrying amounts of the loans on such date. In accordance with the accounting for troubled debt restructurings, the Company derecognized the remaining principal and accrued interest associated with the loans and recognized the equity interests issued to the shareholders at fair value. The fair value of the equity interests issued was determined using the closing price of the Company’s Common Stock of $ 0.36 on the conversion notice date. The difference in value between the carrying value of the loans and the fair value of consideration transferred was accounted for as a capital transaction with related parties and no gain or loss was recognized related to this TDR. As such, the net carrying value of $ 0.7 million was reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversions took place in June 2025. F- 22 Loans Payable Insurance Premium Loans On November 7, 2024, the Company entered into a financing agreement with First Insurance Funding (“FIF”) to finance certain of its annual insurance premiums. The Company financed $ 0.3 million, which were to be paid over a ten-month period with the first payment due on December 7, 2024 . The financing had an interest rate of 7.7 % and FIF has a security interest in the underlying policies that have been financed. This financing was paid as of December 31, 2025. On November 8, 2025, the Company entered into a financing agreement with FIF to finance certain of its annual insurance premiums. The Company financed $ 0.3 million, which will be paid over a ten-month period with the first payment due on December 8, 2025 . The financing has an interest rate of 7.4 % and FIF has a security interest in the underlying policies that have been financed. Extension Loans The Company assumed Data Knights’ liabilities at the closing of the Business Combination, which included existing loan extensions to related parties. The loan extensions were to be either repaid in cash or, at the option of the lender, exchanged for a fixed amount of Common Stock at a price of $ 10.00 per share upon the closing of a business combination or a similar event. At the closing of the Business Combination, all lenders provided notice to have their loans converted into shares upon the filing of a registration statement on Form S-1 with the SEC. On June 19, 2025, two related party investors agreed to convert $ 2.6 million of loan extensions outstanding into 3,650,248 shares of Common Stock at an agreed-upon conversion price of $ 0.71 per share. At the time of the conversion notices, the Company was experiencing financial difficulties (see Note 5), and a concession was granted to the Company because the fair value of the equity interests received by the investors was less than the carrying amounts of the loan extensions on such date. In accordance with the accounting for troubled debt restructurings, the Company derecognized the remaining balance associated with the loans and recognized the equity interests issued to the related parties at fair value. The fair value of the equity interests was determined using the closing price of the Company’s Common Stock of $ 0.36 per share on the conversion notice date. The difference in value between the carrying value of the loans and the fair value of consideration transferred was accounted for as a capital transaction with related parties and no gain or loss was recognized related to this TDR. As such, the net carrying value of $ 2.6 million was reclassified to stockholders’ deficit in the consolidated balance sheets at the time the conversions took place in June 2025. On July 11, 2025, the Company entered into an amended loan extension agreement with a former lender to the Company related to $ 0.1 million of the outstanding balance. Under the original terms of the loan extension agreement, the loan did not bear interest and matured upon the closing of the Business Combination. As amended, the extension loan bears an interest rate of 6.0 % with a maturity date of June 15, 2027 . The Company has agreed to make 24 consecutive monthly payments beginning on July 15, 2025 in equal installments of $4,413, which includes principal plus accrued and unpaid interest. The amendment was accounted for as a debt modification in accordance with ASC 470-50 because the change in cash flows with interest were not substantially different from the original terms without interest. As a result, no gain or loss was recognized and there were no new or previously capitalized debt issuance costs to be amortized over the term of the new debt instrument. Stock Repurchase Loan In February 2024, the Company entered into a stock repurchase agreement with a former holder of Legacy ONMD convertible notes pursuant to which the Company repurchased 187,745 shares of Common Stock in exchange for a promissory note of $ 0.5 million. The $ 0.5 million represents the principal and accrued interest outstanding on the holder’s convertible debt immediately prior to the Business Combination. The Company made payments of $ 0.1 million in July and October 2024 and $ 0.3 million remained outstanding as of December 31, 2024. F- 23 On July 15, 2025, the Company entered into an amended promissory note related to the $ 0.3 million stock repurchase loan outstanding. Under the original terms of the promissory note, the obligation did not bear interest and matured on July 30, 2024. As amended, the loan bears an interest rate of 7.0 % dating back to March 1, 2024 with a maturity date of June 15, 2028 . The Company has agreed to make 36 consecutive monthly payments beginning on July 15, 2025 in equal installments of $11,378, which includes principal plus accrued and unpaid interest. The Company determined this transaction was not a troubled debt restructuring as there were no concessions granted to the Company. Instead, the amendment was accounted for as a debt extinguishment in accordance with ASC 470-50 because the change in cash flows with interest were substantially different from the original terms without interest. As a result, the Company recognized $ 41,216 of debt extinguishment loss during the year ended December 31, 2025 from this amendment. The Company made payments totaling $ 68,270 after the amendment, which included $ 39,460 of principal and $ 28,810 of interest. Helena Notes On March 28, 2024, the Company entered into a definitive securities purchase agreement (the “Helena SPA”) with Helena Global Investment Opportunities 1 Ltd. (“Helena”), an affiliate of Helena Partners Inc., a Cayman Islands-based advisor and investor providing for up to $ 4.5 million in funding through a private placement for the issuance of senior secured convertible notes and warrants across multiple tranches. The Helena SPA was subsequently terminated in June 2024 prior to the closing of any tranches (the “Helena Termination Agreement”). As such, except as described below, the Helena SPA had no impact on the Company’s consolidated financial statements as of and for the year ended December 31, 2024. Pursuant to the Helena Termination Agreement, the Company agreed to issue to Helena a warrant to purchase 50,000 shares of Common Stock at an exercise price of $ 1.20 per share (the “Helena Termination Warrants”) and agreed to reimburse Helena for certain reasonable and documented out-of-pocket legal fees and expenses incurred in connection with entry into the Helena SPA and Helena Termination Agreement and related documents. The Helena Termination Warrants were issued in December 2024 and the Company recorded stock warrant expense of $ 0.04 million in its consolidated statements of operations, which is presented within other (income) expenses, net and included in the other expense caption. See additional information on the accounting for the warrants in Note 10. The Company also incurred legal fees and expenses of $ 0.04 million in connection with the Helena Termination Agreement. The Helena Termination Warrants were fully exercised in October 2025 (see Note 10). Line of Credit In March 2024, the Company obtained a line of credit of $ 1.0 million with BOC Bank to support short-term working capital needs. The line of credit bore an interest rate of 5.0 % and was to mature in 120 days. In July 2024, the maturity date was extended an additional 120 days to November 2, 2024. The line of credit was terminated at maturity in November 2024 and there was no balance outstanding as of December 31, 2024. The Company incurred $ 0.02 million in loan fees, which were amortized over the access period and included in general and administrative expenses in the consolidated statements of operations. Canadian Emergency Business Loan Act (“CEBA”) During December 2020, the Company applied for and received a $ 0.06 CAD ($ 0.04 USD) equivalent CEBA loan. The loan was provided by the Government of Canada to provide capital to organizations to see them through the challenges related to the COVID-19 pandemic and better position them to return to providing services and creating employment. The loan is unsecured. The loan was interest free through December 31, 2023. If the loan was paid back by January 18, 2024, $ 0.01 million of the loan would have been forgiven. If the loan was not paid back by January 18, 2024, the full $ 0.04 million loan would have been converted to loan repayable over three years with a 5 % interest rate. The loan was paid back prior to January 18, 2024, and the Company recognized a gain on extinguishment of $ 15 thousand, which is presented in other expense (income), net in the consolidated statements of operations for the year ended December 31, 2024. The Company accounted for the loan as debt in accordance with FASB ASC 470, Debt , and accrued interest in accordance with the interest method under FASB ASC 835-30. F- 24 8. Stockholders’ Deficit Common Stock Each share of common stock entitles the stockholder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors. As of December 31, 2025, no dividends had been declared. During the year ended December 31, 2025, the Company issued shares of its Common Stock as follows: ● 1,473,696 shares through a private placement with an institutional investor that closed in September 2024 (as amended through the Warrant Amendment described below). These shares were unissued as of December 31, 2024, and the modified number of shares were issued on January 21, 2025. ● 1,621,555 shares valued at $ 1.4 million through partial conversions of the Yorkville Note with an outstanding principal balance of $ 1.1 million. In addition, 250,000 shares were issued to settle the conversion notice from December 2024 (see Note 7). ● 250,000 shares to a vendor in full satisfaction of $ 0.2 million of accounts payable owed by the Company (see Note 5). ● 3,166,475 shares with a carrying amount of $ 2.3 million through the conversion of loans payable to related parties (see Note 7). ● 1,453,174 shares valued at $ 0.5 million through the conversion of PIPE Notes with an outstanding principal and accrued interest balance of $ 1.7 million (see Note 7). ● 3,650,248 shares with a carrying amount of $ 2.6 million through the conversion of loan extensions with related parties (see Note 7). ● 3,390,923 shares through a private placement transaction with an accredited investor that closed in June 2025 (see further details below). ● 2,857,142 and 581,395 shares through subscription agreements with related party investors that closed in June and August 2025, respectively (see further details below). ● 1,214,032 shares from the partial exercise of pre-funded warrants issued in June 2025 (see Note 10). ● 1,323,530 shares from the full exercise of pre-funded warrants issued in July 2024 (see Note 10). ● 510,670 shares from the partial exercise of pre-funded warrants issued in September 2024 (see Note 10). ● 50,000 shares from the full exercise of the Helena Termination Warrants issued in December 2024 (see Note 7). ● 1,020,880 shares from Advances under the SEPA with Yorkville (see further details below). ● 30,000 shares to a consulting firm for services rendered (see Note 9). ● 970,574 shares to holders of vested RSUs. During the year ended December 31, 2024, the Company issued shares of its Common Stock as follows: ● 277,778 shares to partially settle deferred underwriter fees outstanding from the Business Combination (see further details below). ● 3,598,850 shares through private placements with institutional investors that closed in July 2024 (see further details below). ● 200,000 shares to a holder of vested RSUs. ● 526,312 shares to Yorkville as a commitment fee for the SEPA (see further details below). In addition, the Company repurchased 187,745 shares of Common Stock in exchange for a promissory note of $ 0.5 million (see Note 7). F- 25 Private Placements On July 23, 2024, the Company entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell 1,297,059 shares of its Common Stock at a price of $ 1.0278 per share and pre-funded warrants exercisable for 1,323,530 shares of its Common Stock at an exercise price of $ 1.0278 per share (the “July 2024 Pre-Funded Warrants”). The investor was required to prepay the exercise price for the pre-funded warrants, other than $ 0.0001 per share. The warrants and pre-funded warrants will be exercisable at any time after the date of issuance and will not expire. Holders of pre-funded warrants are entitled to receive dividends, if declared, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Common Stock. On July 25, 2024, the Company entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell 2,301,791 shares of its Common Stock at a price of $ 0.85 per share. The Company received net proceeds of approximately $ 4.5 million from these July 2024 private placements, after deducting offering expenses of $ 0.1 million. On September 24, 2024, the Company entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell to the investor 1,918,591 shares of its Common Stock at a price of $ 0.65 per share, warrants exercisable for 133,095 shares of its Common Stock at an exercise price of $ 0.325 per share (the “September 2024 Warrants”) and pre-funded warrants exercisable for 743,314 shares of its Common Stock at an exercise price of $ 0.65 per share (the “September 2024 Pre-Funded Warrants”). The investor was required to prepay the exercise price for the pre-funded warrants, other than $ 0.0001 per share. The warrants and pre-funded warrants will be exercisable at any time after the date of issuance and will not expire. Holders of pre-funded warrants are entitled to receive dividends, if declared, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Common Stock. The Company received net proceeds of approximately $ 1.7 million, after deducting an immaterial amount of offering expenses. As of December 31, 2024, the Company had not yet issued the 1,918,591 shares of Common Stock in order to keep the investor’s ownership percentage below a defined threshold. The net proceeds of $ 1.7 million was recorded akin to an equity forward sale contract and were included in additional paid-in-capital in stockholders’ deficit in the consolidated balance sheets as it met the criteria for equity accounting under ASC 815. On January 21, 2025, the Company entered into an amendment with the investor, which resulted in the number of shares of Common Stock issuable upon exercise of the September 2024 Pre-Funded Warrants increasing from 743,314 to 1,188,209 (the “Warrant Amendment”). In exchange for the issuance of an additional 444,895 pre-funded warrants, the Company agreed to reduce the number of issuable shares of its Common Stock from 1,918,591 to 1,473,696 . The 1,473,696 shares of Common Stock were issued contemporaneously with the exchange in January 2025. The Company accounted for the exchange as a warrant modification. The total fair value of the September 2024 Pre-Funded Warrants and issuable shares of Common Stock prior to the modification was approximately equal to the fair value after the modification, and therefore, there was no incremental fair value related to the Warrant Amendment. On June 19, 2025, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company agreed to issue and sell 3,390,923 shares of its Common Stock at a price of $ 0.42 per share and pre-funded warrants exercisable for 2,561,457 shares of its Common Stock at an exercise price of $ 0.42 per share (the “June 2025 Pre-Funded Warrants”). The investor was required to prepay the exercise price for the pre-funded warrants, other than $ 0.0001 per share. The warrants and pre-funded warrants will be exercisable at any time after the date of issuance and will not expire. Holders of pre-funded warrants are entitled to receive dividends, if declared, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Common Stock. The Company received net proceeds of approximately $ 2.5 million from the private placement, after deducting an immaterial amount of offering expenses. F- 26 Subscription Agreements – Related Parties On June 20, 2025, the Company entered into subscription agreements with two related party investors, pursuant to which the Company agreed to issue and sell 2,857,142 shares of its Common Stock at a price of $ 0.42 per share. The Company received net proceeds of approximately $ 1.2 million from the related party subscription agreements, after deducting an immaterial amount of offering expenses. On August 29, 2025, the Company entered into a subscription agreement with a related party investor pursuant to which the Company agreed to issue and sell 581,395 shares of its Common Stock at a price of $ 0.86 per share. The Company received net proceeds of approximately $ 0.5 million from the related party subscription agreement, after deducting an immaterial amount of offering expenses. Settlement of Deferred Underwriter Fees In connection with the Business Combination, Data Knights entered into an agreement with their underwriters (“EF Hutton”) whereby EF Hutton agreed to waive the related merger underwriting fees that were payable at closing ($ 4.0 million) in exchange for allocated payments as follows: (i) $ 0.5 million in cash at closing; (ii) a $ 0.5 million promissory note that matured on March 1, 2024; and (iii) a transfer of 277,778 shares of Common Stock, which were valued at the closing stock price of $ 10.89 per share on June 28, 2023. If, five trading days prior to the six-month anniversary, the aggregate VWAP value of the 277,778 shares of Common Stock was lower than the original share value of $ 3.0 million, the Company was obligated to compensate EF Hutton at a new share price equal to the difference in amount on such date. Due to the decrease in share value on the six-month anniversary, the Company was required to either pay to EF Hutton an additional $ 2.8 million or issue to EF Hutton an additional 3,175,000 shares of Common Stock. In January 2024, the Company issued the original 277,778 shares of Common Stock as consideration for $ 0.2 million owed by the Company. In August 2024, the Company made a payment of $ 0.1 million under the promissory note. As of December 31, 2024, the Company was obligated to pay EF Hutton the true-up of either $ 2.8 million or 3,175,000 shares of Common Stock valued at $ 0.88 per share, plus the remaining $ 0.4 million promissory note. Upon the occurrence of an event of default, the promissory note bears interest at a rate of 12.5 % until such event of default is cured. The promissory note remained unpaid upon maturity on March 1, 2024, and the Company recorded interest expense of $ 0.1 million during the year ended December 31, 2024, because of the event of default. As of December 31, 2024, deferred underwriter fee payable totaled $ 3.3 million. On June 5, 2025, the Company entered into an amendment to the agreement with EF Hutton whereby the Company agreed to make a one-time cash payment of $ 0.5 million in full satisfaction of all amounts due under the underwriter agreement. At the time of settlement, the Company was experiencing financial difficulties (see Note 5), and a concession was granted to the Company because the cash received by EF Hutton was less than the carrying amount of the deferred underwriter fees payable. The difference in value between the carrying value of the deferred underwriter fees payable and the cash payment resulted in a gain on troubled debt restructuring of $ 2.8 million in the Company’s consolidated statements of operations. Standby Equity Purchase Agreement On June 17, 2024, the Company and Yorkville entered into the SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $ 25.0 million of its Common Stock, subject to certain limitations and conditions set forth in the SEPA, from time to time, over a 24-month period. Sales of the Common Stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company’s option, and the Company is under no obligation to sell any shares of Common Stock to Yorkville under the SEPA except in connection with notices that may be submitted by Yorkville, in certain circumstances as described below. Upon the satisfaction of the conditions precedent in the SEPA, which include having a resale shelf for shares of Common Stock issued to Yorkville declared effective, the Company has the right to direct Yorkville to purchase a specified number of shares of Common Stock by delivering written notice (each an “Advance”). An Advance may not exceed the greater of (i) 100% of the average of the daily trading volume of the Common Stock on Nasdaq, during the five consecutive trading days immediately preceding the date of the Advance, and (ii) five hundred thousand (500,000) shares of Common Stock. F- 27 Yorkville will generally purchase shares pursuant to an Advance at a price per share equal to 97 % of the VWAP, on Nasdaq during the three consecutive trading days commencing on the date of the delivery of the Advance (unless the Company specifies a minimum acceptable price or there is no VWAP on the subject trading day). The SEPA will automatically terminate on the earliest to occur of (i) the first day of the month next following the 24-month anniversary of the date of the SEPA or (ii) the date on which Yorkville shall have made payment for shares of Common Stock equal to $ 25.0 million. The Company has the right to terminate the SEPA at no cost or penalty upon five trading days’ prior written notice to Yorkville, provided that there are no outstanding advances for which shares of Common Stock need to be issued and the Yorkville Note has been paid in full. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent. As consideration for Yorkville’s commitment to purchase the shares of Common Stock pursuant to the SEPA, the Company paid Yorkville a $ 25 thousand cash structuring fee. In addition, the Company must pay a commitment fee in shares equal to $ 0.5 million. In September 2024, the Company paid an equivalent of the commitment fee by issuing 526,312 shares of Common Stock to Yorkville. In connection with the entry into the SEPA, on June 17, 2024, the Company entered into a registration rights agreement with Yorkville, pursuant to which the Company agreed to file with the SEC no later than August 30, 2024, a registration statement for the resale by Yorkville of the shares of Common Stock issued under the SEPA (including the commitment fee shares). The Company agreed to use commercially reasonable efforts to have such registration statement declared effective within 30 days of such filing and to maintain the effectiveness of such registration statement during the 24-month commitment period. The Company did not have the ability to request any Advances under the SEPA (nor may Yorkville convert the Yorkville Note into Common Stock) until such resale registration statement was declared effective by the SEC, which occurred in July 2025. The SEPA was accounted for as a liability under ASC 815 as it includes an embedded put option and an embedded forward option. The put option is recognized at inception and the forward option is recognized upon issuance of notice for the sale of the Company’s Common Stock. The fair value of the derivative liability related to the embedded put option was estimated at $ 0.2 million at the inception of the agreement and $ 0.2 million and $ 0.4 million as of December 31, 2025 and 2024, respectively. The $ 0.2 million outstanding at December 31, 2025 is classified within short-term liabilities on the consolidated balance sheets because the commitment period expires in less than one year. During the year ended December 31, 2025, the Company delivered multiple advance notices for the sale of 1,020,880 shares of its Common Stock, resulting in cumulative gross proceeds of $ 2.5 million. A derivative asset or liability for each embedded forward option was initially recorded at fair value upon delivery of each advance notice, which was subsequently remeasured with changes in fair value recorded in the consolidated statements of operations until settlement. The Company recognized an aggregate loss of $ 0.03 million related to embedded forward options during the year ended December 31, 2025. The embedded forward option was deemed to have no value at December 31, 2025 and 2024 as there were no outstanding notices for the sale of the Company’s Common Stock. During the year ended December 31, 2024, the Company did not deliver any advance notices under the SEPA. The estimated issuance date fair value and remeasurement adjustment for the embedded put option and embedded forward option are presented as a single line within other (income) expense, net in the accompanying consolidated statements of operations under the caption change in fair value of SEPA derivative liabilities. The embedded put option fair value adjustment was $( 0.2 ) million and $ 0.4 million for the years ended December 31, 2025 and 2024, respectively. The embedded forward option fair value adjustment was $ 0.03 million and $ 0 for the years ended December 31, 2025 and 2024, respectively. ARC Forward Contract As of December 31, 2025 and 2024, the Company had an outstanding forward contract to issue 1,240,644 shares of its Common Stock to ARC Group Limited for success fees earned from Data Knights in connection with the Business Combination. The forward contract was included in additional paid-in-capital in stockholders’ deficit in the consolidated balance sheets as it met the criteria for equity accounting under ASC 815. F- 28 9. Stock Based Compensation In 2023, the Company’s Board of Directors adopted the 2022 Equity Incentive Plan (the “2022 Plan”) and reserved an amount of shares of Common Stock equal to 10% of the number of shares of Common Stock of OneMedNet immediately following the Business Combination. The 2022 Plan is also subject to annual increases to be added on the first day of each fiscal year equal to 5% of the number of outstanding shares on the immediately preceding December 31 (subject to a maximum annual increase of 1,000,000 shares). On January 1, 2025, the number of shares available for issuance under the 2022 Plan was increased by 1,000,000 shares of common stock. There were 3,769,571 stock-based awards available for issuance at December 31, 2025 under the 2022 Plan. Time-Based Stock Options The Company has historically granted stock options to employees, directors, and consultants with vesting subject to continued service over time. Accordingly, stock compensation expense for such awards is recognized using a straight-line attribution model over the vesting term. During the year ended December 31, 2024, the Company granted 147,000 fully vested stock options to a former executive of the Company at an exercise price of $ 1.00 . The stock options were forfeited without exercise 90 days after his termination of service with the Company and they were no longer outstanding at December 31, 2024. There was no other stock option activity during the year ended December 31, 2024, and there was no stock option activity during the year ended December 31, 2025. The Company recorded stock-based compensation expense of $ 0.03 million during the year ended December 31, 2024. The fair value was estimated using the Black-Scholes option pricing, pursuant to which the weighted-average grant date fair value was $ 0.23 . The following table summarizes the assumptions used in calculating the fair value of the stock options granted. Schedule of Stock Options Granted December 31, 2024 Risk-free interest rate 4.5 % Expected dividend yield 0.0 % Expected term in years 2.50 Expected volatility 64.5 % The expected term is applied to the time-based stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among the Company’s employees, directors, and consultants. The risk-free interest rate is based on a U.S. treasury instrument, whose term is consistent with the expected term of the stock options. The Company’s stock price volatility assumption is based on historical volatility of a group of peer companies with similar characteristics to the Company and who have similar risk profiles and positions within the industry. The Company accounts for forfeitures as they occur. As of December 31, 2025, there was no unrecognized stock compensation related to unvested stock options. Time-Based RSUs The Company has historically granted RSUs to employees, directors, and consultants with vesting subject to continued service over time. Accordingly, stock compensation expense for such awards is recognized using a straight-line attribution model over the vesting term. The fair value of each time-based RSU is based on the closing price of the Company’s Common Stock on the date of grant. The following table summarizes activity for time-based RSUs for the year ended December 31, 2025: Schedule of Restricted Stock Awards Weighted Number of Average Grant Awards Date Fair Value Unvested at December 31, 2024 1,067,125 $ 0.52 Granted 2,566,043 1.33 Vested ( 1,239,078 ) 0.84 Cancelled ( 59,650 ) 0.43 Unvested at December 31, 2025 2,334,440 $ 1.24 F- 29 During the year ended December 31, 2025, the Company issued a total of 970,574 shares of its Common Stock to settle vested RSUs, of which 518,278 were vested but not yet issued as of December 31, 2024. As of December 31, 2025, there were a total of 876,812 RSUs that were vested but had not yet been settled by the Company. The fair value of time-based RSUs vested during the year ended December 31, 2025 was $ 1.0 million. As of December 31, 2025, the total unrecognized compensation related to unvested time-based RSUs granted was $ 1.8 million, which the Company expects to recognize over a weighted-average period of approximately 2.50 years. Shares Issued to Consulting Firm In November 2025, the Company issued 30,000 shares of Common Stock to a consulting firm for approximately 6 months of services. The Company recorded stock-based compensation expense of $ 0.1 million related to this arrangement for the year ended December 31, 2025. The fair value was determined using the closing price of the Company’s Common Stock of $ 2.34 on the grant date. As of December 31, 2025, there was no unrecognized stock compensation related to this arrangement. The Company recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the periods presented (in thousands): Schedule of Stock-based Compensation Expense Year Ended December 31, 2025 2024 Cost of revenue $ 55 $ 17 General and administrative 1,787 585 Sales and marketing 75 6 Research and development 115 20 Total stock-based compensation expense $ 2,032 $ 628 10. Stock Warrants The Company has the following warrants outstanding for the periods presented: Schedule of Warrants Outstanding As of December 31, 2025 2024 Liability Classified Warrants Business Combination Warrants 585,275 585,275 PIPE Warrants 95,744 95,744 Subtotal 681,019 681,019 Equity Classified Warrants Public Warrants 11,500,000 11,500,000 Private Placement Warrants 2,158,059 2,199,939 Helena Termination Warrants - 50,000 Subtotal 13,658,059 13,749,939 Grand Total 14,339,078 14,430,958 Warrants outstanding 14,339,078 14,430,958 Business Combination Warrants In connection with the closing of the Business Combination on November 7, 2023, the Company assumed 585,275 private warrants to purchase Common Stock with an exercise price of $ 11.50 per share (the “Business Combination Warrants”). The Business Combination Warrants (and shares of Common Stock issued or issuable upon exercise of the Business Combination Warrants) in general were not transferable, assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain redemption scenarios by the Company so long as they are held by the Sponsor or their respective permitted transferees. Otherwise, the Business Combination Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price, exercisability and exercise period. If the Business Combination Warrants are held by holders other than the Sponsor, Metric or their respective permitted transferees, the Business Combination Warrants will be redeemable by the Company under all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. F- 30 The Company accounts for the Business Combination Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the Business Combination Warrants do not meet the criteria for equity treatment thereunder, each Business Combination Warrant must be recorded as a liability. The accounting treatment of derivative financial instruments in accordance with ASC 815, Derivatives and Hedging, required that the Company record a derivative liability upon the closing of the Business Combination. Accordingly, the Company classifies each Business Combination Warrant as a liability at its fair value. This liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the Business Combination Warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the Business Combination Warrants will be reclassified as of the date of the event that causes the reclassification. As of December 31, 2025 and 2024, all 585,275 Private Placement Warrants remained outstanding. PIPE Warrants In connection with the PIPE Notes described in Note 7, the Company also issued 95,745 warrants to purchase Common Stock (“PIPE Warrants”). The Company accounts for the PIPE Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. The accounting treatment of derivative financial instruments in accordance with ASC 815, Derivatives and Hedging, requires that the Company record a derivative liability upon issuance of the warrants. Accordingly, the Company classifies each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value. This liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. As of December 31, 2025 and 2024, all 95,745 PIPE Warrants remain outstanding. Public Warrants In connection with the closing of the Business Combination on November 7, 2023, the Company assumed 11,500,000 public warrants (the “Public Warrants”) to purchase Common Stock with an exercise price of $ 11.50 per share. The Public Warrants became exercisable 30 days after the Closing of the Business Combination. Each Public Warrant is exercisable for one share of Common Stock. F- 31 The Company may redeem the outstanding Public Warrants for $ 0.01 per Public Warrant upon at least 30 days’ prior written notice of redemption given after the Public Warrants become exercisable, if the reported last sale price of the Common Stock equals or exceeds $ 18.00 per share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing after the Public Warrants become exercisable and ending on the third trading day before the Company sends the notice of redemption to the holders of the Public Warrants. Upon issuance of a redemption notice by the Company, the holders of the Public Warrants may, at any time after the redemption notice, exercise the Public Warrants on a cashless basis. The Public Warrants are classified as equity, with the fair value of the Public Warrants as of the date of the Business Combination closed to additional paid-in capital. As of December 31, 2025 and 2024, all 11,500,000 Public Warrants remain outstanding. Private Placement Warrants As described in Note 10, the Company issued the July 2024 Pre-Funded Warrants, the September 2024 Pre-Funded Warrants, the September 2024 Warrants and the June 2025 Pre-Funded Warrants in connection with the July 2024, September 2024 and June 2025 private placements (together, the “Private Placement Warrants”). The Private Placement Warrants are classified as equity in accordance with ASC Subtopic 815-40, Derivatives and Hedging - Contracts in Entity’s Own Equity (“ASC 815-40”). On January 21, 2025, the September 2024 Pre-Funded Warrants were amended to increase the number of warrants issued to the investor by 444,895 shares. The Warrant Amendment had no accounting impact because the number of issuable shares of Common Stock were decreased by the same number of shares and both instruments have approximately the same fair value. See Note 8 for further details. On August 21, 2025, the Company issued 1,214,032 shares of Common Stock in connection with the partial exercise of the June 2025 Pre-Funded Warrants. As of December 31, 2025, 1,347,425 of the June 2025 Pre-Funded Warrants remain outstanding. On August 22, 2025, the Company issued 1,323,530 shares of Common Stock in connection with the full exercise of July 2024 Pre-Funded Warrants. On the same day, the Company issued 510,670 shares of Common Stock to the same investor in connection with the partial exercise of the September 2024 Pre-Funded Warrants. As of December 31, 2025, 677,539 of the September 2024 Pre-Funded Warrants remain outstanding. As of December 31, 2025 and 2024, 2,199,939 and 2,158,059 Private Placement Warrants remain outstanding, respectively. Helena Termination Warrants In connection with the Helena Termination Agreement described in Note 7, the Company issued 50,000 warrants purchase Common Stock at an exercise price of $ 1.20 per share. The Helena Termination Warrants became immediately upon issuance on December 4, 2024. Each Helena Termination Warrant is exercisable for one share of Common Stock. The Helena Termination Warrants are classified as equity in accordance with ASC 815-40, with the fair value on the date of issuance recorded to stock warrant expense as a cost to terminate the Helena SPA. On October 7, 2025, the Company issued 25,000 shares of Common Stock in connection with the partial exercise of the Helena Termination Warrants. On October 15, 2025, the Company issued an additional 25,000 shares of Common Stock in connection with the exercise of the remaining Helena Termination Warrants. The Company received gross proceeds of $ 60,000 in connection with these exercises. As of December 31, 2025, the Helena Termination Warrants were fully exercised and none remain outstanding. F- 32 11. Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, inclusive of related party (in thousands): Schedule of Assets and Liabilities Measured at Fair Value Level 1 Level 2 Level 3 Total December 31, 2025 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 35 $ - $ - $ 35 Bitcoin 506 - - 506 Total assets, at fair value $ 541 $ - $ - $ 541 Liabilities: Business Combination Warrants $ - $ - $ 60 $ 60 PIPE Warrants - - 11 11 SEPA put option liability - - 186 186 Total liabilities, at fair value $ - $ - $ 257 $ 257 Level 1 Level 2 Level 3 Total December 31, 2024 Level 1 Level 2 Level 3 Total Assets: Bitcoin $ 2,849 $ - $ - $ 2,849 Total assets, at fair value $ 2,849 $ - $ - $ 2,849 Liabilities: Business Combination Warrants $ - $ - $ 12 $ 12 PIPE Warrants - - 3 3 PIPE Notes - - 1,734 1,734 Yorkville Note - - 1,718 1,718 SEPA put option liability - - 434 434 Total liabilities, at fair value $ - $ - $ 3,901 $ 3,901 Cash Equivalents As of December 31, 2025, cash equivalents are comprised of money market funds, which are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. The Company had no cash equivalents as of December 31, 2024. Business Combination Warrants and PIPE Warrants The following table presents the changes in the Business Combination Warrants and PIPE Warrants measured at fair value during the year ended December 31, 2025 (in thousands): Schedule of Warrants and Notes Measured at Fair Value Business Combination Warrants PIPE Warrants Balance, December 31, 2024 $ 12 $ 3 Changes in fair value 48 8 Balance, December 31, 2025 $ 60 $ 11 The Company remeasured the fair value of the Business Combination Warrants and PIPE Warrants at December 31, 2025 using the Black-Scholes option-pricing model with the following assumptions: Schedule of Fair Value Assumptions and Valuation Warrants Warrants As of December 31, 2025 PIPE Business Combination Warrants Warrants Stock price $ 1.10 $ 1.10 Exercise price $ 10.00 $ 11.50 Expected volatility 85.0 % 85.0 % Weighted average risk-free rate 3.5 % 3.5 % Expected dividend yield 0.0 % 0.0 % Warrants measurement input 0.0 % 0.0 % Expected term (in years) 2.85 2.85 F- 33 PIPE Notes and Yorkville Note The following table presents the changes in the PIPE Notes and Yorkville Note measured at fair value during the year ended December 31, 2025 (in thousands): PIPE Notes Yorkville Note Balance, December 31, 2024 $ 1,734 $ 1,718 Conversions to Common Stock (1) ( 513 ) ( 1,392 ) Cash repayment - ( 262 ) Changes in fair value ( 1,221 ) ( 64 ) Balance, December 31, 2025 $ - $ - The estimated fair values of the PIPE Notes and Yorkville Note are determined based on the aggregated, probability-weighted average of the outcomes of certain possible scenarios. The combined value of the probability-weighted average of those outcomes is then discounted back to each reporting period in which the convertible notes are outstanding, in each case, based on a risk-adjusted discount rate estimated based on the implied discount rate. The discount rate was held constant over the valuation periods given the fact pattern associated with the Company and the stage of development. SEPA Derivative Liabilities The following table presents the changes in the SEPA derivative liabilities measured at fair value during the year ended December 31, 2025 (in thousands): SEPA Put Option Liability SEPA Forward Option Liability Balance, December 31, 2024 $ 434 $ - Changes in fair value ( 248 ) 32 Conversions to Common Stock - ( 32 ) Balance, December 31, 2025 $ 186 $ - The estimated fair value of the SEPA put option liability was determined using a Monte Carlo simulation model in order to project the future path of the Company’s stock price over the commitment period with the following assumptions: 2025 2024 As of December 31, 2025 2024 Term (in years) 0.5 1.5 Starting stock price $ 1.10 $ 1.36 Expected volatility 144.0 % 132.5 % Risk-free rate 3.6 % 4.2 % Derivative liability 3.6 % 4.2 % The SEPA forward option liability was deemed to have no value at December 31, 2025 and 2024 as there were no outstanding notices for the sale of the Company’s Common Stock. 12. Related Party Transactions PIPE Notes and Warrants As disclosed in Note 7, Data Knights issued and sold PIPE Notes in connection with the Business Combination, which are convertible into shares of the Company’s Common Stock. Total proceeds raised from the PIPE Notes were $ 1.5 million, of which $ 1.0 million were with related party investors. In June 2025, all holders of PIPE Notes agreed to convert the outstanding principal and accrued interest into 1,453,174 shares of Common Stock, of which 972,326 shares were issued to these related party investors. See Note 7 for further details. F- 34 In connection with the issuance of the PIPE Notes, the Company also issued a total of 95,744 shares of PIPE Warrants, of which 63,829 shares were issued to the same related party investors. Refer to Note 10 for additional details on the terms of the PIPE Warrants. Shareholder Loans As described in Note 7, the Company received gross proceeds of $ 1.6 and $ 0.7 million in connection with convertible and non-convertible shareholder loans, respectively, with two related party investors between 2023 and 2024. In June 2025, these investors agreed to convert the outstanding balance into an aggregate of 3,166,476 shares of Common Stock. See Note 7 for further details. Loan Extensions At the closing of the Business Combination, the Company assumed Data Knights’ liabilities, which included existing loan extensions to related parties. In June 2025, two related party investors agreed to convert their outstanding balances under the loan extension agreements into an aggregate of 3,650,248 shares of Common Stock. See Note 7 for further details. Subscription Agreements As described in Note 8, the Company issued 3,438,537 shares of Common Stock in exchange for gross proceeds of $ 1.7 million pursuant to subscription agreements with two related party investors in June and August 2025. See Note 8 for further details. Other Related Party Transactions Accounting Services – The Company engages an accounting firm to provide accounting and bookkeeping services, which is majority owned by the Company’s Chief Financial Officer (“CFO”), who serves as an independent contractor to the Company. For the years ended December 31, 2025 and 2024, the Company incurred expenses of $ 0.03 million and $ 0.01 million, respectively, related to services provided by the CFO’s accounting firm. Such amounts are included in general and administrative expenses in the accompanying consolidated statements of operations. As of December 31, 2025 and 2024, there were no amounts payable to the accounting firm. Software Development Services – The Company engages a software development company to provide software development services, which is wholly owned by the Company’s Chief Technology Officer (“CTO”), who is an employee of the Company. For the years ended December 31, 2025 and 2024, the Company incurred expenses of $ 0.2 million and $ 0.1 million, respectively, for software development services provided by the CTO’s company. Such amounts are included in research and development expense in the accompanying consolidated statements of operations. As of December 31, 2025 and 2024, amounts payable to the CTO’s software development company were $ 0.05 million and $ 0.2 million, respectively, and are included in accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the year ended December 31, 2025, the Company settled $ 0.2 million of trade payables owed to this vendor by issuing 250,000 shares of its Common Stock (see Note 5). The shares were issued at their fair value on the settlement date, which totaled $ 0.1 million, resulting in a $ 0.1 million gain. The gain was recognized within gain on troubled debt restructurings in the accompanying consolidated statements of operations because the payables related to services previously provided by the vendor in the ordinary course of business. The terms of the settlement were negotiated and approved by management other than the CTO and the CTO does not have the ability to unilaterally bind the Company. As such, the substance of the transaction was a settlement of a commercial obligation, not a capital contribution. F- 35 The Company believes that the terms of its arrangements with these vendors are consistent with those that would have been obtained from unaffiliated third parties. 13. Commitments and Contingencies Lease Agreement The Company has a month-to-month lease for a suite at a cost of $ 530 per month. The Company incurred $ 7,743 and $ 7,830 of rent expense, including common tenant costs and cancellation costs, during the years ended December 31, 2025 and 2024, respectively. Litigation From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recognized, if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. On November 6, 2025, ARC Group Limited and ARC Opportunity Fund Limited (together, “ARC”) filed a complaint against the Company and certain officers of the Company in the District Court of Minnesota, Fourth Judicial District (the “ARC Complaint”). The ARC Complaint alleges that the Company has breached certain contracts that the Company entered into with ARC before the closing of the Business Combination, including certain financial advisory contracts entered into by the Company at the direction of the sponsor of the Business Combination (the “sponsor”; the Company notes that the sponsor is an affiliate of ARC). Specifically, the ARC Complaint asserts that the Company breached these contracts by issuing certain shares of Common Stock to ARC contemporaneously with the closing of the Business Combination and improperly cancelling those shares after the Business Combination as well as by failing to pay ARC certain cash amounts when due. The ARC Complaint seeks an order of specific performance requiring the Company to reinstate the cancelled shares of Common Stock or, in the alternative, compensatory damages for such cancellation as well as payment of the other purported amounts due. The ARC Complaint also asserts tort claims arising out of the Company’s actions and seeks compensatory damages (plus prejudgment interest) and punitive damages in connection with such claims but does not specify an amount of damages. The Company notes that no shares of Common Stock were actually issued to ARC prior to or contemporaneously with the closing of the Business Combination and that, as of December 31, 2025 and 2024, the Company has recorded a forward contract to issue 1,240,644 shares of its Common Stock to ARC for success fees earned in connection with the Business Combination (see Note 8). As of December 31, 2025 and 2024, the Company has recorded aggregate cash liabilities payable to ARC equal to $ 0.4 million. The Company intends to vigorously defend itself against the claims in the ARC Complaint in excess of these amounts. The Company is also assessing whether there are any counterclaims available to it arising out of self-dealing transactions between ARC and the sponsor. Accordingly, the Company has not recorded any additional liability arising out of the ARC Complaint as the Company does not believe any incremental loss is probable, and the Company cannot estimate any reasonably possible loss or range of possible loss. On March 19, 2026, ARC voluntarily dismissed the complaint without prejudice. The Company was not subject to any other material legal proceedings during the years ended December 31, 2025 and 2024. 14. Subsequent Events The Company has evaluated subsequent events occurring through March 30, 2026, the date the consolidated financial statements were available to be issued, for events requiring recording or disclosure in the Company’s consolidated financial statements. During February 2026, the Company sold an aggregate of 400,000 shares of its Common Stock to Yorkville pursuant to advance notices delivered under the SEPA at a price of $ 1.19 per share. The Company received gross proceeds of approximately $ 0.5 million in connection with these issuances. F- 36 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure None.